Take home message: {#sec1}
==================

•In our analysis, 12.5% of patients with muscle-invasive bladder cancer (MIBC) had a delay over 90 days (median 111 days) from transurethral resection of bladder tumor (TURBT) to starting definitive intent chemoradiation therapy (CRT)•Treatment delays over 90 days were more common for patients living in rural communities and for those living a further distance to treatment facility•We observed no difference in overall survival between patients treated with earlier CRT compared to those with delayed CRT•During pandemics such as COVID-19, short strategic delays in starting CRT can be considered on a case-by-case basis to reduce the patient's risk of contracting the infection. Clinician judgment is critical in making these decisions

Introduction {#sec2}
============

To mitigate exposure risk during the COVID-19 pandemic, the National Comprehensive Cancer Network (NCCN) and several physician organizations have recommended alternative treatment approaches including hypofractionated radiation therapy (RT) and delaying or omitting daily RT for several cancers, including breast, prostate, and skin cancer, with many of these guidelines recommending a 3-month delay for patients who are relatively asymptomatic without rapidly progressive disease([@bib1], [@bib2], [@bib3]). To our knowledge, at the time of submission of this paper, no guidelines have been released for recommendations regarding non-operative management of muscle-invasive bladder cancer (MIBC). To make informed decisions about whether to delay definitive chemoradiation (CRT) of MIBC during this pandemic, risk assessment of potential COVID-19 associated morbidity and mortality from contracting COVID-19 in the clinic setting versus cancer morbidity and mortality is necessary. Given that most patients with bladder cancer are elderly/former smokers, their risk of COVID-19 complications is relatively high ([@bib4]). In the recent publication by Kuderer et al, patients with cancer and COVID-19 had high 30-day all-cause mortality and independent factors associated with increased 30-day mortality included increased age, male sex, smoking history, active cancer, multiple comorbidities, and poorer performance status ([@bib5]). While several retrospective cystectomy series suggest that 2-3-month delays in the setting of neoadjuvant chemotherapy (NAC) are not associated with worse outcomes ([@bib6], [@bib7]), it is unknown whether delays in chemoradiation (CRT) for MIBC affects survival. In clinical practice, it has been estimated that the first fraction of definitive RT occurs 82 days (IQR, 62-105) after transurethral resection of bladder tumor (TURBT) ([@bib8]) and the currently enrolling SWOG 1806 trial of CRT allows delays of up to 77 days ([@bib9]). The optimal timing of CRT after TURBT has not been determined. In this study, we sought to determine if there is an association between the timing of CRT initiation and overall survival (OS). We hypothesized that delays in initiating definitive CRT following TURBT may not be associated with decreased overall survival.

Patients and Methods: {#sec2.1}
---------------------

We identified cT2-4N0M0 MIBC patients between 18-90 years-old in the National Cancer Database's most recent bladder cancer participant user file (PUF), which included data from 2004-2015, who underwent TURBT and curative intent concurrent CRT therapy (55 Gy in 20 fractions or ≥ 60 Gy with conventional fractionation). Chemotherapy had to start within 14 days of RT, and patients who received neoadjuvant chemotherapy were excluded. All patients underwent TURBT within 30 days of diagnosis (eFigure_1). Patients were grouped based on timing of CRT: ≤89 days after TURBT ('earlier') vs. ≥ 90 & \<180 days after TURBT ('delayed'). Patient and demographic characteristics included: age, sex, race, facility type, facility location, metro/urban/rural population, income, education level, insurance status, distance from treatment center, Charlson‐Deyo comorbidity index (CCI), year of diagnosis, T-stage, number of chemotherapy agents, and Earlier CRT/Delayed CRT. Patients with missing demographic, treatment, or survival data were excluded from the analysis. The chi‐squared test was used to compare categorical demographic and patient characteristics between the two groups. The Student\'s *t-*test was used to compare continuous variables between groups. Multivariable logistic regression was used to identify predictors of delayed CRT. To account for lead time bias, OS was calculated from time of starting radiotherapy until death, censoring at last follow‐up for patients who were alive. The Kaplan‐Meier method was used to estimate overall survival probabilities. Variables included in the multivariable Cox proportional hazards model were chosen due to clinical relevance and the proportional hazards assumption was found to be met. Sensitivity analyses were performed. We repeated the analysis with delay from TURBT to CRT as a continuous, rather than dichotomized, variable. We also repeated the analysis with overall survival defined as time from diagnosis until death, censoring at last follow-up for patients still alive. *p*\<0.05 was considered significant. All were two‐sided. Analysis was performed using SPSS (IBM, Armonk, NY).

Results {#sec3}
=======

1,584 patients were eligible for analysis: 1,387 (87.5%) receiving earlier CRT (median 45 days post-TURBT, IQR: 34-59 days) and 197 (12.5%) receiving delayed CRT (median 111 days post-TURBT, IQR: 98-130 days). Of the delayed CRT cohort, 130 patients (66.0%) were delayed 90-120 days and 24 patients (12.2%) were delayed \>150 days. Baseline patient characteristics are listed in Table_1. Multivariable logistic regression showed that covariables associated with increased likelihood for treatment delays included patients living in rural counties (OR, 2.52; 95% HR, 1.09-5.80; p=0.030) and increasing distance in miles from residence to treatment facility (OR, 1.01; 95% HR, 1.00-1.01; p=0.008). Covariables associated with less likelihood of delayed CRT included: younger age (OR, 0.98; 95% HR, 0.96-0.99; p=0.010) and higher education \[(7-12.9% rate of not graduating high-school: OR, 0.56; 95% HR, 0.32-0.97; p=0.038);(\<7% rate of not graduating high-school: OR, 0.47; 95% HR, 0.24-0.91; p=0.024)\].

Median OS calculated from date of starting CRT was 29.0 months (95%CI, 26.0-32.0) for earlier CRT versus 27.0 months (95%CI, 19.75-34.24) for delayed CRT (p=0.94) ([Figure_1](#fig1){ref-type="fig"} ). On multivariable analysis, delayed CRT was not associated with an OS difference compared to earlier CRT (HR, 1.05; 95% CI, 0.87-1.27; p=0.60)([Table_1](#tbl1){ref-type="table"} ). Increasing age, higher comorbidity score, and cT3/4 disease were associated with worse overall survival (p\<0.04 each covariable).Figure 1Unadjusted overall survival for earlier vs. delayed chemo-radiation for muscle-invasive bladder cancer. Overall survival was measured from the start of CRT.Table1Patient CharacteristicsMultivariable AnalysisEarlier CRT (N=1,387)Delayed CRT (N=197)P-valueHazard Ratio (95% CI)P-valueEarlier CRTNo. (%) of patientsNo. (%) of patientsMedian, \[IQR\] (days)45 \[34-59\]\-\-\-\-\-\-\-\-\-\--Reference\-\-\-\--Delayed CRTMedian, \[IQR\] (days)\-\-\-\--111 \[98-130\]\-\-\-\-\--1.05 (0.87-1.27)0.601Age**0.011**Mean, \[SD\] (years)76.3 \[9.4\]74.5 \[9.4\]1.03 (1.02-1.03)**\<0.0001**Sex0.825Male1,042 (75.1)150 (76.1)Reference\-\-\-\--Female345 (24.9)47 (23.9)1.01 (0.88-1.16)0.670Race0.254White1,286 (92.7)178 (90.4)Reference\-\-\-\--Other101 (7.3)19 (9.6)1.14 (0.91-1.44)0.260Facility Type**0.024**Community CC177 (12.8)18 (9.1)Reference\-\-\-\--Comprehensive Community CC684 (49.4)83 (42.1)0.96 (0.79-1.16)0.670Academic/Research CC326 (23.5)63 (32)1.04 (0.85-1.30)0.696Integrated Network CC198 (14.3)33 (16.8)1.05 (0.83-1.33)0.696Facility Location0.346East638 (46.0)102 (51.8)Reference\-\-\-\--Central519 (37.4)65 (33.0)1.07 (0.93-1.23)0.355West230 (16.6)30 (15.2)0.92 (0.77-1.11)0.391Median Income0.795\< \$38,000210 (15.1)33 (16.8)Reference\-\-\-\--\$38,000-47,999339 (24.4)50 (25.4)1.00 (0.80-1.23)0.949\$48,000-62,999397 (28.6)50 (25.4)0.95 (0.76-1.18)0.628\$63,000+442 (31.9)64 (32.5)0.99 (0.76-1.29)0.934Education^∗^0.13821% or more180 (13.0)37 (18.8)Reference\-\-\-\--13-20.9%324 (23.4)47 (23.9)1.19 (0.96-1.48)0.1097-12.9%505 (36.4)67 (34.0)1.11 (0.88-1.39)0.386\<7%378 (27.3)46 (23.4)0.98 (0.75-1.28)0.867Urban/rural^\#^0.097Metro counties1,125 (81.1)155 (78.7)Reference\-\-\-\--Urban counties169 (12.2)23 (11.7)1.04 (0.86-1.27)0.688Rural counties68 (4.9)10 (5.1)0.96 (0.75-1.34)0.994Unknown25 (1.8)9 (4.6)0.67 (0.42-1.09)0.104Insurance Status0.445Private Insurance15 (1.1)2 (1.0)Reference\-\-\-\--Not Insured213 (15.4)39 (19.8)0.91 (0.44-1.87)0.790Medicaid33 (2.4)3 (1.5)1.31 (0.58-2.96)0.517Medicare1,102 (79.5)148 (75.1)1.01 (0.49-2.08)0.981Other Government24 (1.7)5 (2.5)1.25 (0.54-2.92)0.604Distance from residence to treatment**\<0.0001**Mean \[SD\] (miles)19.4 \[67\]46.3 \[207.7\]1.00 (1.00-1.00)0.884Charlson-Deyo Comorbidity Score0.7450911 (65.7)123 (62.4)Reference\-\-\-\--1318 (22.9)51 (25.9)1.26 (1.09-1.46)**0.002**2108 (7.8)17 (8.6)1.63 (1.31-2.03)**\<0.0001**\>250 (3.6)6 (3.0)2.36 (1.73-3.21)**\<0.0001**Year of Diagnosis0.7382004-06282 (20.3)37 (18.8)Reference\-\-\-\--2007-09331 (23.9)51 (25.9)0.95 (0.80-1.12)0.5442010-12318 (22.9)40 (20.3)0.97 (0.81-1.16)0.7302013-15456 (32.9)69 (35.0)1.04 (0.87-1.25)0.652Clinical T-stage0.108T21,150 (82.9)175 (88.8)Reference\-\-\-\--T3135 (9.7)12 (6.1)1.24 (1.01-1.52)**0.038**T4102 (7.4)10 (5.1)1.60 (1.28-1.98)**\<0.0001**Chemotherapy**0.004**Single-agent830 (59.9)142 (72.1)Reference\-\-\-\--Multiagent458 (33.0)46 (23.4)0.96 (0.84-1.09)0.517No. Agents unknown99 (7.1)9 (4.6)0.97 (0.76-1.22)0.781[^1][^2][^3]

As a sensitivity analysis, earlier CRT and delayed CRT were removed from the model and replaced with days between TURBT and CRT as a continuous variable. In the multivariable model, increasing days from TURBT and CRT was not associated with decreased OS (HR, 1.0; 95% CI, 0.99-1.01; p=0.192). There was also no difference in OS when calculated from date of diagnosis for earlier CRT vs. delayed CRT (P=0.45). On multivariable analysis using OS calculated from date of diagnosis, results were comparable (Delayed CRT: HR 0.98, 95% CI, 0.80-1.17; p=0.745).

Discussion: {#sec4}
===========

During the COVID-19 pandemic, providers and patients must engage in shared decision-making to ensure that the benefit of early intervention for MIBC to prevent tumor progression exceeds the risk of contracting COVID-19 in the clinic setting, especially for patients requiring daily radiation therapy. In our analysis, we were unable to find any differences in OS between earlier CRT for MIBC and delayed CRT ≥90 days (median 111 days) despite multiple methods of analyzing the data, suggesting that a moderate delay from TURBT (∼90 days) may be feasible during the COVID-19 pandemic or during other times when a short delay in treatment is being considered by the patient or provider.

To our knowledge, this is the first study to evaluate the effect of treatment delay on survival for MIBC patients treated with definitive CRT. Our findings are consistent with a number of published series looking at the effect of treatment delay for NAC plus radical cystectomy (RC) patients, although there is not consensus in the cystectomy literature on the effect of treatment delay on survival. Several larger surgical series reported either no association between delays and survival for patients treated with NAC and RC ([@bib6]), or no impact when the delay was \<5 months ([@bib7]). A SEER analysis, by contrast, reported that cT2N0 patients who underwent RC more than 11 weeks after NAC had worse OS than patients who underwent earlier RC(10). For patients treated with RC alone, treatment delays may be associated with worse outcomes, but results in the literature are mixed ([@bib10], [@bib11], [@bib12], [@bib13], [@bib14]). It may be hypothesized that delays in cystectomy patients who do not receive NAC may lead to tumor progression and higher rates of positive margins or lymph node metastases which in turn decrease survival, whereas radiotherapy with radiosensitizing chemotherapy can effectively treat a larger target volume with less risk for a marginal miss than cystectomy.

This observational study has several limitations, many of which are inherent to the retrospective, non-randomized nature of the analysis. Firstly, it should be noted that the only method to definitively determine the effect of delays in CRT on OS is a randomized trial powered to detect such a difference. While we found no difference in OS for patients who had delayed CRT, this data was not prospectively collected nor randomized and powered to detect such a difference. Another notable limitation of the NCDB is that there is no reporting on oncologic outcomes such as recurrence-free survival, progression-free survival, or salvage cystectomy rates ([@bib15]). It is therefore unclear if patients who were delayed had worse cancer-specific mortality even if their OS did not appear to be affected. Given the retrospective design using a population-based database, analyses are subject to selection biases and imbalances in measured and unmeasured variables. However, multivariable modeling was utilized to address potential confounding. Relatively few patients (12.2%) were delayed \>150 days, so the impact of such a long delay is not well understood. Another limitation is the lack of key variables which are not included in the NCDB, including detailed information regarding extent and outcomes of the TUBRT as well as radiation treatment volumes (e.g. elective nodal irradiation vs bladder alone). Comprehensive information on chemotherapeutic agents (e.g. cisplatin vs non-cisplatin based) and their dosing are also not available in the NCDB. Surveillance schedules are also lacking in the NCDB. Lastly, the median OS for patient's in our cohort is lower than would be expected for trimodality bladder preservation in cystectomy candidates who have lower competing mortality risk due to other causes. It is unclear whether the results of this study would apply to trimodality bladder preservation patients. Caution should also be taken when applying these findings to more locally advanced disease (cT3/4) given the limited number of such patients included in the delayed CRT group (N=22).

Conclusion {#sec5}
==========

While a long treatment delay may result in upstaging, symptomatic progression and worse survival, we were unable to show a worse OS for MIBC patients treated with delayed CRT between 90 and 180 days from TURBT (median 111 days). During pandemics such as COVID-19, both hypofractionated CRT (e.g. 55 Gy/20 fractions), when feasible, and short, strategic delays in starting CRT can be considered on a case-by-case basis to reduce the patient's risk of contracting the infection. Clinician judgment is critical in making these decisions.
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[^1]: CRT, chemoradiation therapy; No., number of patients; CI, confidence interval; IQR, interquartile range; SD, standard deviation; CC, cancer center

[^2]: ^∗^Education -- measure of number of adults in patient's zip code who did not graduate high-school

[^3]: ^\#^Urban/rural -- Defined per United States Department of Agriculture Economic Research Service; Metro, counties in metropolitan areas; Urban, counties in urban areas; Rural, counties with less 2,500 population
